{"url_path":"/sec/anvs/8-k/2026-06-17/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-075198-index.html","accession_number":"0001104659-26-075198","cik":"0001477845","ticker":"ANVS","issuer_name":"Annovis Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1477845/0001104659-26-075198-index.html","primary_entity_key":"0001477845","primary_entity_name":"Annovis Bio, Inc."},"word_count":312,"has_tables":true,"body_markdown":"false\n0001477845\n\n0001477845\n\n2026-06-17\n2026-06-17\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, DC 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\n \n\n**Date of report (Date\nof earliest event reported): June 17,\n2026**\n\n \n\n**ANNOVIS BIO, INC.**\n\n**(Exact Name of Registrant as Specified in Charter)** \n\n \n\n**Delaware**\n**001-39202**\n**26-2540421**\n\n**(State or Other Jurisdiction**\n\n**of Incorporation)**\n\n**(Commission**\n\n**File Number)**\n\n**(I.R.S. Employer**\n\n**Identification No.)**\n\n** **\n\n**101\nLindenwood Drive****, Suite 225****Malvern****, PA****19355**\n\n**(Address of Principal Executive Offices, and\nZip Code)**\n\n** **\n\n**(484) 875-3192**\n\n**Registrant’s Telephone Number, Including\nArea Code**\n\n** **\n\n**                       Not\nApplicable                       **\n\n**(Former Name or Former Address, if Changed Since\nLast Report)** \n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**\n**Trading Symbol(s)**\n**Name\nof each exchange on which registered**\n\n**Common Stock, par value $0.0001 per share**\n**ANVS**\n**New York Stock Exchange**\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction\nA.2. below):\n\n \n\n \n¨\nWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n \n¨\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n \n¨\nPre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨Pre-commencement communication pursuant to Rule 13e-4(c) under\nthe Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised\nfinancial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}